| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,827 | 0,886 | 15:25 | |
| 0,827 | 0,886 | 15:22 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | XFRA R3X1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| Mo | Opus Genetics Reports Positive Phase 3 Results For Night Vision Therapy, Stock Up | ||
| Mo | XFRA R3X1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILOPUS GENETICS DL-... ► Artikel lesen | |
| Mo | Opus Genetics reports success in night vision trial | ||
| Mo | Opus Genetics, Inc.: Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions | Study met primary endpoint of =15-letter (=3-line) gain in mesopic low contrast distance visual acuity in comparison to placeboPhase 3 study showed patient-reported functional benefit in treating... ► Artikel lesen |
